$gmab
Genmab's stock is seeing significant social media buzz, with X driving most of the engagement. Discussions are focused on upcoming earnings and antibody-drug conjugate mechanisms, though a critical theme highlights a trial failure for their drug Epkinly.
About $gmab
Genmab is a biotechnology company focused on developing and manufacturing antibody therapeutics.
Engagements: [------] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [-----]
[--] Month: [-------] +20%
[--] Months: [---------] +69%
[--] Year: [---------] +20%
1-Year High: [-------] on 2025-09-29
1-Year Low: [---] on 2025-12-14
Engagements by network (24h): Reddit: [--] X: [------] YouTube: [--]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
1-Year High: [---] on 2025-11-08
1-Year Low: [--] on 2025-04-19
Mentions by network (24h): Reddit: [--] X: [--] YouTube: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $gmab in the last [--] hours which is up 25% from [--] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2025-11-08
1-Year Low: [--] on 2025-04-19
The most influential creators that mention $gmab in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @MarcJacksonLA | [--] | [-----] | [--] | [---] |
| @EarningsSeason_ | [--] | [---] | [--] | [---] |
| @NightOwlBiotech | [--] | [-----] | [--] | [--] |
| @investingportfoliopathway | [--] | [---] | [--] | [--] |
| @EgidiusLambrech | [--] | [---] | [--] | [--] |
| @JacobPlieth | [--] | [------] | [--] | [--] |
Sentiment: 67%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 67%
Daily Average: 83%
[--] Month: 100% +22%
[--] Months: 100% no change
[--] Year: 100% +17%
1-Year High: 100% on 2025-03-04
1-Year Low: 42% on 2025-11-29
Most Supportive Themes:
- Earnings Calendar Mentions: (33%) A list of companies with upcoming earnings reports.
- Antibody-Drug Conjugate (ADC) Mechanisms: (33%) Discussion of the mechanisms behind antibody-drug conjugates, a type of cancer therapy.
Most Critical Themes:
- Epkinly Trial Failure: (33%) Genmab's drug Epkinly has failed a confirmatory test.
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing